Mutational analysis of FBXO7 gene in Parkinson's disease in a Taiwanese population

Neurobiology of Aging

Volumn 34, Issue 6, 2013, Pages 1713.e1-1713.e4

  Lin, Chin Hsien ^a   Chen, Meng Ling ^a,b   Lai, Tzu Ting ^c   Tai, Chun Hwei ^a   Wu, Ruey Meei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

F box protein; FBXO7; PARK15; Parkinson's disease; Taiwanese

Indexed keywords

ARGININE; ASPARTIC ACID; CYTOSINE; ISOLEUCINE; THREONINE; THYMINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; COHORT ANALYSIS; CONTROLLED STUDY; EXON; FBXO7 GENE; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; IDIOPATHIC DISEASE; INTRON; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; TAIWAN; TAIWANESE;

EID: 84875247685     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.12.023     Document Type: Article

References (20)

1. Chang Y.F., Cheng C.M., Chang L.K., Jong Y.J., You C.Y. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination. Biochem. Biophys. Res. Commun. 2006, 342:1022-1026.
2. Di Fonzo A., Dekker M.C., Montagna P., Baruzzi A., Yonova E.H., Correia Guedes L., Szczerbinska A., Zhao T., Dubbel-Hulsman L.O., Wouters C.H., de Graaff E., Oyen W.J., Simons E.J., Breedveld G.J., Oostra B.A., Horstink M.W., Bonifati V. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009, 72:240-245.
3. Ebrahimi-Fakhari D., Wahlster L., McLean P.J. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta. Neuropathol. 2012, 124:153-172.
4. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
5. Ho M.S., Ou C., Chan Y.R., Chien C.T., Pi H. The utility F-box for protein destruction. Cell Mol. Life Sci. 2008, 65:1977-2000.
6. Houlden H., Singleton A.B. The genetics and neuropathology of Parkinson's disease. Acta. Neuropathol. 2012, 124:325-338.
7. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
8. Kirk R., Laman H., Knowles P.P., Murray-Rust J., Lomonosov M., Meziane el K., McDonald N.Q. Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor. J. Biol. Chem. 2008, 283:22325-22335.
9. Lee M.J., Mata I.F., Lin C.H., Tzen K.Y., Lincoln S.J., Bounds R., Lockhart P.J., Hulihan M.M., Farrer M.J., Wu R.M. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. J. Biomed. Sci. 2008, 15:661-667.
10. Lee M.J., Mata I.F., Lin C.H., Tzen K.Y., Lincoln S.J., Bounds R., Lockhart P.J., Hulihan M.M., Farrer M.J., Wu R.M. Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism. Mov. Disord. 2009, 24:104-108.
11. Lin C.H., Chen M.L., Chen G.S., Tai C.H., Wu R.M. Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. Hum. Genet. 2011, 130:817-827.
12. Lin C.H., Tsai P.I., Wu R.M., Chien C.T. LRRK2 Parkinson's disease: from animal models to cellular mechanisms. Rev. Neurosci. 2011, 22:411-418.
13. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
14. Luo L.Z., Xu Q., Guo J.F., Wang L., Shi C.H., Wei J.H., Long Z.G., Pan Q., Tang B.S., Xia K., Yan X.X. FBXO7 gene mutations may be rare in Chinese early-onset Parkinsonism patients. Neurosci. Lett. 2010, 482:86-89.
15. Paisán-Ruiz C., Guevara R., Federoff M., Hanagasi H., Sina F., Elahi E., Schneider S.A., Schwingenschuh P., Bajaj N., Emre M., Singleton A.B., Hardy J., Bhatia K.P., Brandner S., Lees A.J., Houlden H. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov. Disord. 2010, 25:1791-1800.
16. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055.
17. Shojaee S., Sina F., Banihosseini S.S., Kazemi M.H., Kalhor R., Shahidi G.A., Fakhrai-Rad H., Ronaghi M., Elahi E. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am. J. Hum. Genet. 2008, 82:1375-1384.
18. Wu R.M., Bounds R., Lincoln S., Hulihan M., Lin C.H., Hwu W.L., Chen J., Gwinn-Hardy K., Farrer M. Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. Arch. Neurol. 2005, 62:82-87.
19. Zheng N., Schulman B.A., Song L., Miller J.J., Jeffrey P.D., Wang P., Chu C., Koepp D.M., Elledge S.J., Pagano M., Conaway R.C., Conaway J.W., Harper J.W., Pavletich N.P. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002, 416:703-709.
20. Zhu L.H., Luo X.G., Zhou Y.S., Li F.R., Yang Y.C., Ren Y., Pang H. Lack of association between three single nucleotide polymorphisms in the PARK9, PARK15, and BST1 genes and Parkinson's disease in the northern Han Chinese population. Chin. Med. J. (Engl) 2012, 125:588-592.